高级糖化终产物可溶性受体与糖尿病之间的关系:系统回顾和荟萃分析。

IF 2.8 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Qimou Chen, Liehua Liu, Weijian Ke, Xuhui Li, Haipeng Xiao, Yanbing Li
{"title":"高级糖化终产物可溶性受体与糖尿病之间的关系:系统回顾和荟萃分析。","authors":"Qimou Chen, Liehua Liu, Weijian Ke, Xuhui Li, Haipeng Xiao, Yanbing Li","doi":"10.1186/s12902-024-01759-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>In both type 1 diabetes (T1DM) and type 2 diabetes (T2DM), previous studies have yielded inconsistent findings regarding whether the levels of the soluble receptor for advanced glycation end products (sRAGE) are significantly altered. This meta-analysis aims to systematically evaluate the changes of sRAGE levels in patients with T1DM and T2DM.</p><p><strong>Methods: </strong>PubMed, Embase, and Web of Science were systematically searched from inception until April 2024. We included studies reporting sRAGE levels in individuals with T1DM or T2DM, using non-diabetic healthy individuals as the control group. A random-effects model was applied to conduct a meta-analysis of effect measures (means and SDs).</p><p><strong>Results: </strong>49 datasets from 32 studies, involving 4948 subjects, met the inclusion criteria. A random-effects model meta-analysis showed that sRAGE levels in T1DM subjects (SMD 0.45, CI: 0.16-0.73, P = 0.002) and T2DM subjects with complications (SMD 1.59, CI: 0.77-2.41, P = 0.0001) were significantly higher than those in the control groups. No statistically significant change in sRAGE levels was observed in T2DM subjects without complications (SMD 0.01, CI: -0.61-0.64, P = 0.97). A decrease in sRAGE levels was observed in subjects with newly diagnosed T2DM (SMD-0.40, CI: -0.71- -0.09, P = 0.01).</p><p><strong>Conclusion: </strong>This meta-analysis indicated that sRAGE levels increased in T1DM patients and T2DM patients with complications, while they decreased in newly diagnosed T2DM patients. No significant difference was observed in T2DM patients without complications. Clearly, changes in sRAGE levels in patients with T1DM or T2DM are not uniform, but depend on the different types and stages of the disease.</p><p><strong>Prospero registration number: </strong>CRD42024521252.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"24 1","pages":"232"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523792/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association between the soluble receptor for advanced glycation end products and diabetes mellitus: systematic review and meta-analysis.\",\"authors\":\"Qimou Chen, Liehua Liu, Weijian Ke, Xuhui Li, Haipeng Xiao, Yanbing Li\",\"doi\":\"10.1186/s12902-024-01759-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>In both type 1 diabetes (T1DM) and type 2 diabetes (T2DM), previous studies have yielded inconsistent findings regarding whether the levels of the soluble receptor for advanced glycation end products (sRAGE) are significantly altered. This meta-analysis aims to systematically evaluate the changes of sRAGE levels in patients with T1DM and T2DM.</p><p><strong>Methods: </strong>PubMed, Embase, and Web of Science were systematically searched from inception until April 2024. We included studies reporting sRAGE levels in individuals with T1DM or T2DM, using non-diabetic healthy individuals as the control group. A random-effects model was applied to conduct a meta-analysis of effect measures (means and SDs).</p><p><strong>Results: </strong>49 datasets from 32 studies, involving 4948 subjects, met the inclusion criteria. A random-effects model meta-analysis showed that sRAGE levels in T1DM subjects (SMD 0.45, CI: 0.16-0.73, P = 0.002) and T2DM subjects with complications (SMD 1.59, CI: 0.77-2.41, P = 0.0001) were significantly higher than those in the control groups. No statistically significant change in sRAGE levels was observed in T2DM subjects without complications (SMD 0.01, CI: -0.61-0.64, P = 0.97). A decrease in sRAGE levels was observed in subjects with newly diagnosed T2DM (SMD-0.40, CI: -0.71- -0.09, P = 0.01).</p><p><strong>Conclusion: </strong>This meta-analysis indicated that sRAGE levels increased in T1DM patients and T2DM patients with complications, while they decreased in newly diagnosed T2DM patients. No significant difference was observed in T2DM patients without complications. Clearly, changes in sRAGE levels in patients with T1DM or T2DM are not uniform, but depend on the different types and stages of the disease.</p><p><strong>Prospero registration number: </strong>CRD42024521252.</p>\",\"PeriodicalId\":9152,\"journal\":{\"name\":\"BMC Endocrine Disorders\",\"volume\":\"24 1\",\"pages\":\"232\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523792/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Endocrine Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12902-024-01759-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Endocrine Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12902-024-01759-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:在 1 型糖尿病(T1DM)和 2 型糖尿病(T2DM)患者中,关于高级糖化终产物可溶性受体(sRAGE)的水平是否会发生显著变化,以往的研究结果并不一致。本荟萃分析旨在系统评估 T1DM 和 T2DM 患者体内 sRAGE 水平的变化:方法:系统检索了从开始到 2024 年 4 月的 PubMed、Embase 和 Web of Science。我们以非糖尿病健康人为对照组,纳入了报道 T1DM 或 T2DM 患者 sRAGE 水平的研究。采用随机效应模型对效应指标(均值和标度)进行荟萃分析:共有 32 项研究的 49 个数据集符合纳入标准,涉及 4948 名受试者。随机效应模型荟萃分析显示,T1DM 受试者(SMD 0.45,CI:0.16-0.73,P = 0.002)和有并发症的 T2DM 受试者(SMD 1.59,CI:0.77-2.41,P = 0.0001)的 sRAGE 水平显著高于对照组。在无并发症的 T2DM 受试者中,sRAGE 水平未观察到有统计学意义的变化(SMD 0.01,CI:-0.61-0.64,P = 0.97)。新诊断的 T2DM 患者的 sRAGE 水平下降(SMD-0.40,CI:-0.71--0.09,P = 0.01):这项荟萃分析表明,T1DM 患者和有并发症的 T2DM 患者的 sRAGE 水平升高,而新诊断的 T2DM 患者的 sRAGE 水平降低。在无并发症的 T2DM 患者中未观察到明显差异。显然,T1DM 或 T2DM 患者体内 sRAGE 水平的变化并不一致,而是取决于疾病的不同类型和阶段:CRD42024521252。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between the soluble receptor for advanced glycation end products and diabetes mellitus: systematic review and meta-analysis.

Background and aims: In both type 1 diabetes (T1DM) and type 2 diabetes (T2DM), previous studies have yielded inconsistent findings regarding whether the levels of the soluble receptor for advanced glycation end products (sRAGE) are significantly altered. This meta-analysis aims to systematically evaluate the changes of sRAGE levels in patients with T1DM and T2DM.

Methods: PubMed, Embase, and Web of Science were systematically searched from inception until April 2024. We included studies reporting sRAGE levels in individuals with T1DM or T2DM, using non-diabetic healthy individuals as the control group. A random-effects model was applied to conduct a meta-analysis of effect measures (means and SDs).

Results: 49 datasets from 32 studies, involving 4948 subjects, met the inclusion criteria. A random-effects model meta-analysis showed that sRAGE levels in T1DM subjects (SMD 0.45, CI: 0.16-0.73, P = 0.002) and T2DM subjects with complications (SMD 1.59, CI: 0.77-2.41, P = 0.0001) were significantly higher than those in the control groups. No statistically significant change in sRAGE levels was observed in T2DM subjects without complications (SMD 0.01, CI: -0.61-0.64, P = 0.97). A decrease in sRAGE levels was observed in subjects with newly diagnosed T2DM (SMD-0.40, CI: -0.71- -0.09, P = 0.01).

Conclusion: This meta-analysis indicated that sRAGE levels increased in T1DM patients and T2DM patients with complications, while they decreased in newly diagnosed T2DM patients. No significant difference was observed in T2DM patients without complications. Clearly, changes in sRAGE levels in patients with T1DM or T2DM are not uniform, but depend on the different types and stages of the disease.

Prospero registration number: CRD42024521252.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMC Endocrine Disorders
BMC Endocrine Disorders ENDOCRINOLOGY & METABOLISM-
CiteScore
4.40
自引率
0.00%
发文量
280
审稿时长
>12 weeks
期刊介绍: BMC Endocrine Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of endocrine disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信